AU2013200020B2 - Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid - Google Patents

Abstract

C:\NRPortbl\DCC\TXS\31654731. DOC-3/09/2010 COMPOSITIONS FOR LOCALIZED THERAPY OF THE EYE, COMPRISING PREFERABLY TRIAMCINOLONE ACETONIDE AND HYALURONIC ACID Abstract Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that 10 facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, 15 and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

Description

WO 2005/072701 PCT/US2005/001371 COMPOSITIONS FOR LOCALIZED THERAPY OF THE EYE, COMPRISING PREFERABLY TRIAMCINOLONE ACETONIDE AND HYALURONIC ACID The present invention relates to compositions that 5. are delivered to the posterior segment of an eye of a human or animal. More particularly, the invention relates to compositions including one or more poorly soluble therapeutic agents present in particles that are sized and/or distributed to provide localized therapy to 10 the posterior of an eye. Corticosteroids, among other agents, are utilized to treat a wide variety of ophthalmic diseases that affect the posterior segment of an eye. Examples of some diseases treated with corticosteroids includes: 15 central retinal vein occlusion (CRVO) , branch retinal vein occlusion (BRVO) , choroidal macular edema (CME), diabetic macular edema (DME), diabetic macular retinopathy, uveitis, telangitis, and age related macular degeneration (ARMD) as well as other diseases of 20 the posterior segment. In treating ocular diseases or disorders, steroids can be administered systemically, however systemic administration of steroids is often associated with side effects that are generally too great for ophthalmic use. 25 Thus, topical, suprachoroidal, subconjunctival, retrobulbar, and intravitreal administration have also been studied. Although direct intravitreal administration of current therapeutic agents may address some problems 30 associated with systemic administration, intravitreal WO 2005/072701 PCT/US2005/001371 2 adminis-tration of existing ophthalmic compositions may result in ocular hypertension, as well as steroid glaucoma and posterior subcapsular cataracts, when steroids are administered. For example, approximately 5 25% of patients receiving intraocular corticosteroid therapy will experience an elevation of intraocular pressure (IOP) with about 10% of the patients having an IOP as high as 28 to 30 mm Hg. The IOP is thought to be due to- increased outflow resistance resulting from 10 changes in the trabecular meshwork cells. The ocular hypertension is particularly common in "steroid responders". In addition, the formulation currently used in clinical practice contains excipients that are toxic to 15 the internal ocular structures. For example, Kenalog*, is a commercially available formulation of triamcinolone acetonide containing such undesirable excipients. Kenalog has been shown to cause ERG changes in rabbits and its preservative, benzyl alcohol, has been 20 implicated in such changes. The desired site of action for therapeutic agents administered to the posterior segment of an eye generally, and corticosteroids in particular, is the retinal pigmented epithelium (RPE). The RPE is a single 25 cell layer responsible for maintenance of the blood retinal barrier as well as subretinal fluid volume and composition. The cells of the RPE comprise the outer blood retinal barrier and are joined by zonulae occludente tight junctions. As such, permeation of 30 compounds into the RPE is quite limited. Thus, WO 2005/072701 PCT/US2005/001371 3 regardless of the administration route, penetration of a therapeutic agent through the outer blood-retinal barrier is limited. To overcome these limitations extremely high and potentially toxic doses of drugs are 5 frequently used. In certain situations, drugs are administered by controlled or sustained release technologies to attempt to increase their duration of action or reduce the toxicity of transient high general concentrations. 10 Some poorly soluble therapeutic agents, such as corticosteroids, however, are well tolerated locally and have a prolonged duration of action by virtue of their own intrinsic dissolution rates. For example, triamcinolone acetonide has been successfully 15 administered by direct intravitreal injection do to its slow dissolution rate and tolerability. Unfortunately, side effects from the existing triamcinolone acetonide formulation include endophthalmitis as well as retinal toxicity from the benzyl alcohol preservative. Glaucoma 20 and cataract are also observed. Reducing the lens concentration of a corticosteroid may help mitigate the cataractogenic potential of these drugs. Additionally, reducing the anterior segment concentration of the corticosteroids relative to the 25 posterior concentrations may reduce the chance of elevating the TIGR (MYOC, GLC1A) gene activity in the trabecular meshwork thought to be associated with steroid induced glaucoma. Thus, there is a need for new compositions for 30 injection into the posterior segments of eyes of humans H:\mdt\Interwoven\NRPortbl\DCC\MDT\6428241_1.doc-17/06/2014 4 or animals and methods for providing desired therapeutic effects in the posterior segments of eyes of humans or animals. Summary of the Invention 5 New compositions and methods for treating posterior segments of eyes of humans or animals have been discovered. The present compositions are highly suitable for intravitreal administration into the posterior segments of eyes and provide localized therapeutic effects to the posterior portion of an eye and 10 reduced adverse side-effects to anterior structures or tissues of an eye. In a first aspect, the present invention provides a pharmaceutical composition for placement in a posterior segment of an eye of a human or animal, the composition comprising: 15 a therapeutic component comprising particles of a poorly soluble therapeutic agent and hyaluronic acid or a salt thereof, the particles having a size effective to form concentrated regions of the therapeutic agent in the retinal pigmented epithelium (RPE) of an eye of a human or animal when administered 20 to a posterior segment of the eye of the human or animal, wherein the therapeutic agent is not triamcinolone In a second aspect, the present invention provides a method of treatment comprising administering the composition defined in the first aspect to a posterior segment of an eye of a human or 25 animal, thereby obtaining a desired therapeutic effect. In a third aspect, the present invention provides a pharmaceutical composition for placement in a posterior segment of an eye of a human or animal, the composition comprising: a therapeutic component comprising particles of a poorly 30 soluble steroid and hyaluronic acid or a salt thereof, wherein the particles are sized and distributed in the composition to form concentrated regions of the steroid in the retinal pigmented epithelium (RPE) of the human or animal when administered to a posterior segment of the eye of the human or animal, wherein the 35 poorly soluble steroid is not triamcinolone.

H:\mdt\Interwoven\NRPortbl\DCC\MDT\6428241_1.doc-17/06/2014 4a In a fourth aspect, the present invention provides a use of a composition as defined in the first aspect or a pharmaceutical composition as defined in the third aspect in the manufacture of a medicament for treating an ocular condition. 5 in one broad embodiment, the present compositions include a therapeutic component that includes a therapeutic agent in the form of or present in particles. The particles are sized to form one or more concentrated regions of the therapeutic agent in the RPE of an eye of a human or animal patient. The particles are 10 sized to be phagocytized or pinocytized by the cells of the RPE, thereby circumventing the blood-retinal barrier to treat ocular diseases or disorders. In certain embodiments, the therapeutic agent is a steroid, such as a corticosteroid. The particles may include a combination of a poorly soluble 15 therapeutic agent and an ophthalmically acceptable polymer component. For example, a composition may include a triamcinolone acetonide in combination with a particulate polymer, such as a bead. In another embodiment, the therapeutic agent may be WO 2005/072701 PCT/US2005/001371 5 formed as particles in a vehicle suspension or carrier. For example, and in at least one embodiment, the particles comprise a combination of a corticosteroid and a polysaccharide, such as hyaluronic acid. In other 5 words, the particles may include particles of a corticosteroid that have been stabilized with hyaluronic acid. The particles may have a size less than about 3000 nanometers, and in certain embodiments, the particles may have a size less than about 200 10 nanometers. In another embodiment, an ophthalmically acceptable composition comprises a population of particles of triamcinolone acetonide having an effective average particle size less than about 3000 nanometers. In one 15 specific embodiment, the particles are formed by subjecting or exposing the triamcinolone acetonide to hyaluronic acid. In an additional embodiment, a population of particles including triamcinolone acetonide is provided. 20 The population of particles has an effective average particle size less than ' about 3000 nanometers. The particles may be provided in a liquid vehicle or carrier component before administration to an eye. One example of such a carrier component includes hyaluronic acid. 25 The particles and carrier component may also be provided in a dispensing apparatus prior to administration to an eye. Methods of treating patients are also disclosed and are included within the scope of the present invention. 30 In general, such methods comprise administering, 'e.g.

WO 2005/072701 PCT/US2005/001371 6 injecting a particulate therapeutic agent-containing composition, for example, a composition in accordance with the present intention, to a posterior segment of an eye of a human or animal. Such administering is 5 effective in providing a desired therapeutic effect. The administering step advantageously comprises at least one of intravitreal injecting, subconjunctival injecting, sub-tenon injecting, retrobulbar injecting, suprachoroidal injecting and the like. 10 Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention provided that the features included in such a combination are not mutually inconsistent. In addition, 15 any feature or combination of features may be specifically excluded from any embodiment of the present invention. These and other aspects and -advantages of the present invention are apparent in the following detailed 20 description, examples and claims. Detailed Description The present invention involves compositions, such as ophthalmic compositions, that provide therapy to a 25 patient. In accordance with the disclosure herein, compositions are disclosed that are useful for placement, preferably by injection, into a posterior segment of an eye of a human or animal, and preferably a living human or animal. Such compositions in the 30 posterior, e.g., vitreous, of the eye are WO 2005/072701 PCT/US2005/001371 7 therapeutically effective against one or more conditions and/or diseases of the posterior of the eye, and/or one or more symptoms of such conditions and/or diseases of the posterior of the eye, among other things. 5 In general, the present compositions comprise a therapeutic component which comprises a poorly soluble therapeutic agent in the form of or present in small particles. The particles typically have a size, for example, a length, a width, a diameter, a cross 10 sectional area, a surface area, or a volume, on the order of micrometers or nanometers. The therapeutic agent may be shaped or otherwise manufactured as particles, or may be coupled to particles of other materials. The particles including the therapeutic 15 agent have a size that is effective to form concentrated regions of the therapeutic agent in the retinal pigmented epithelium (RPE) of an eye to which the composition or particles are administered. The concentrated regions of the therapeutic agent are 20 effective to provide a desired therapeutic effect to the human or animal, such as a therapeutic effect to a posterior portion of the eye. In comparison, existing pharmaceutical compositions which are used to provide ocular therapy contain a 25 therapeutic agent which does not form concentrated regions of the therapeutic agent in the RPE of an eye. Thus, the ophthalmically-acceptable pharmaceutical compositions disclosed herein are effective to provide more localized drug delivery to a posterior portion of 30 an eye of a patient relative to existing compositions WO 2005/072701 PCT/US2005/001371 8 containing a substantially identical therapeutic agent. The concentrated regions of the poorly soluble therapeutic agent are localized to the posterior portion of an eye of a patient, such as the RPE. In certain 5 aspects, the particles are sized to form one or more discrete regions of concentrated therapeutic agent in the RPE relative to other regions of the RPE. In other words, administration of the particles disclosed herein to a posterior portion of an eye of a patient may result 10 in one or more areas of the RPE having a relatively higher concentration of therapeutic agent, and one or more regions having a relatively lower concentration of therapeutic agent. The concentrated regions may be understood to be or 15 to function as RPE depots of the therapeutic agent. By sizing the particles appropriately to form concentrated regions of the therapeutic agent, the delivery of the therapeutic agent to the patient can be prolonged for periods of time, such as days, weeks, or months. Thus, 20 the particles disclosed herein may be effective to provide extended-release of the therapeutic agent into the posterior portion of the eye. The release rate may be substantially continuous occurring by relatively passive biological and/or chemical processes, or the 25 release rate may be discontinuous, for example pulsatile or periodic, to achieve a desired therapeutic effect. In certain embodiments, the composition comprises a therapeutically effective amount of the therapeutic agent before the composition is administered to an eye. 30 In. other embodiments, the composition may comprise a WO 2005/072701 PCT/US2005/001371 9 sub-therapeutically effective amount of the therapeutic agent before it is administered to the eye, and the concentrated regions of the therapeutic agent are formed to have a therapeutically effective amount of the 5 therapeutic agent. In other words, the concentrated regions may have a concentration of the therapeutic agent that is greater than the concentration of the therapeutic - agent of the composition before the composition is administered to an eye. 10 The concentrated regions may also have a concentration of the therapeutic agent that is greater relative to the concentration of the therapeutic agent in the composition when the composition is administered to the eye, for example, the concentration of the 15 therapeutic agent that is present in the vitreous of the eye. In addition, or alternatively, the concentrated regions may have a concentration of particles that is greater than the concentration of the particles in the 20 composition, either before administration to the eye, or after administration to the eye and as present in the vitreous of the -eye. The concentrated regions of the therapeutic agent may be effective to provide an enhanced therapeutic effect relative to substantially 25 identical compositions in which the therapeutic agent is not provided as particles, or as particles having the same or similar sizes to that disclosed herein. For example, the therapeutic agent may be present in the composition in an amount of at least about 10 mg 30 per ml of the composition. One advantage of certain WO 2005/072701 PCT/US2005/001371 10 embodiments of the present invention is the effective ability of the present compositions to include relatively smaller amounts or concentrations of the therapeutic agent in the composition while obtaining a 5 relatively larger amount or concentration of the therapeutic agent at a target site, such as the RPE. Thus, the therapeutic agent may be present in the present compositions in an amount in the range of about 1% or less to about 5% or about 10% or about 20% or 10 about 25% or about 30% or more (w/v) of the composition. In accordance with the disclosure herein, reduced amounts of the composition may be required to be placed or injected into the posterior segment of the eye in order to provide the same amount or more therapeutic 15 agent in the posterior segment of the eye relative to existing compositions, such as Kenalog*-40. The particles including the therapeutic agent are sized so that the particles are distributed in the composition when administered to the eye to reduce 20 toxicity associated with the therapeutic agent in the anterior tissues of the eye, such as the lens, the iris ciliary body, the aqueous humor, and the like. Thus, by sizing the particles appropriately, a targeted delivery of the therapeutic agent can be obtained that is 25 effective to reduce, and preferably prevent, toxicity to anterior structures of the eye. Examples of therapeutic agents that can be formed as particles, as disclosed herein, include, without limitation, any conventional poorly soluble ophthalmic 30 therapeutic agent. Such therapeutic agents WO 2005/072701 PCTUS2005/001371 - 11 advantageously have a limited solubility in a fluid, such as water, for example, at 25 0 C or at 37 0 C. For example, the therapeutic agent preferably has a solubility in water at 25 0 C or at 37*C of less than 10 5 mg/ml. Of course, the therapeutic agent should be ophthalmically acceptable, that is, should have substantially no significant or undue detrimental effect of the eye structures or tissues. For example, therapeutic agents may include 10 retinoids, prostaglandins, tyrosine kinase inhibitors, adrenoreceptor agonists or antagonists, dopaminergic agonists, cholinergic agonists, carbonic anhydrase inhibitors, guanylate cyclase activators, cannabinoids, endothelin, adenosine agonists, antianagiogenic 15 compounds, angiostatic compounds, and neuroprotectants. When a therapeutic agent is not poorly soluble, it may be physically or chemically modified to become poorly soluble using conventional methods known to persons of ordinary skill in the art. 20 More specifically, the therapeutic agent may include non-steroidal anti-inflammants, analgesics, or antipyretics; antihistamines, antibiotics, beta blockers, steroids, such as corticosteroids, anti neoplastic agents, immunosupressive agents, antiviral 25 agents, and antioxidants. Non-limiting examples of non-steroidal anti inflammants, analgesics, and antipyretics, include aspirin, acetaminophen, ibuprofen, naproxen, diclofenac, etodolac, fenoprofen, indomethacin, ketoprofen, 30 oxaprozin, piroxicam, sulindac, diflunisal, mefenamic WO 2005/072701 PCT/US2005/001371 12 acid, and derivatives thereof. As used herein, the term "derivative" refers to any substance which is sufficiently structurally similar to the material which it is identified as a derivative so 5 as to have substantially similar functionality or activity, for example, therapeutic effectiveness, as the material when the substance is used in place of the material. The functionality of any derivative disclosed herein may be determined using conventional routine 10 methods well known to persons. of ordinary skill in the art. Examples of antihistamines include, and are not limited to, loradatine, hydroxyzine, diphenhydramine, chlorpheniramine, brompheniramine, cyproheptadine, 15 terfenadine, clemastine, triprolidine, carbinoxamine, diphenylpyral ine, phenindamine, azat adine, tripelennamine, dexchlorpheniramine, dexbrompheniramine, methdilazine, and trimprazine doxylamine, pheniramine, pyrilamine, chiorcyclizine, thonzylamine, and 20 derivatives thereof. Examples of antibiotics include without limitation, cefazolin, cephradine, cefaclor, cephapirin, ceftizoxime, cefoperazone, cefotetan, cefutoxime, cefotaxime, cefadroxil, ceftazidime, cephalexin, 25 cephalothin,, cefamandole, cefoxitin, cefonicid, ceforanide, ceftriaxone, cefadroxil, cephradine, cefuroxime, ampicillin, amoxicillin, cyclacillin, ampicillin, penicillin G, penicillin V potassium, piperacillin, oxacillin, bacampicillin, cloxacillin, 30 ticarcillin, azlocillin, carbenicillin, methicillin, WO 2005/072701 PCT/US2005/001371 13 nafcillin, erythromycin, tetracycline, doxycycline, minocycline, aztreonam, chloramphenicol, ciprofloxacin hydrochloride, clindamycin, metronidazole, gentamicin, lincomycin, tobramycin, vancomycin, polymyxin B sulfate, 5 colistimethate, colistin, azithromycin, augmentin, sulfamethoxazole, trimethoprim, and derivatives thereof. Examples of beta blockers include acebutolol, atenolol, labetalol, metoprolol, propranolol, and derivatives thereof. 10 Examples of corticosteroids include cortisone, prednisolone, triamcinolone, flurometholone, dexamethasone, medrysone, loteprednol, fluazacort, hydrocortisone, prednisone triamcinolone, betamethasone, prednisone, methylprednisolone, triamcinolone acetonide, 15 triamcinolone hexacatonide, paramethasone acetate, diflorasone, fluocinolone and fluocinonide, derivatives thereof, and mixtures thereof. Examples of antineoplastic agents include adriamycin, cyclophosphamide, actinomycin, bleomycin, 20 duanorubicin doxorubicin, epirubicin, mitomycin, methotrexate, fluorouracil, carboplatin, carmustine (BCNU), methyl-CCNU, cisplatin, etoposide, interferons, camptothecin and derivatives thereof, phenesterine, taxol and derivatives thereof, taxotere and derivatives 25 thereof, vinblastine, vincristine, tamoxifen, etoposide, piposulfan, cyclophosphamide, and flutamide, and derivatives thereof. Examples of immunosuppresive agents include cyclosporine, azathioprine, tacrolimus, and derivatives 30 thereof.

WO 2005/072701 PCT/US2005/001371 14 Examples of antiviral agents include interferon gamma, zidovudine, amantadine hydrochloride, ribavirin, acyclovir, valciclovir, dideoxycytidine, and derivatives thereof. 5 Examples of antioxidant agents include ascorbate, alpha-tocopherol, mannitol, reduced glutathione, various carotenoids, cysteine, uric acid, taurine, tyrosine, superoxide dismutase, lutein, zeaxanthin, cryotpxanthin, astazanthin, lycopene, N-acetyl-cysteine, carnosine, 10 gamma-glutamylcysteine, quercitin, lactoferrin, dihydrolipoic acid, citrate, Ginkgo Biloba extract, tea catechins, bilberry extract, vitamins E or esters of vitamin E, retinyl palmitate, and derivatives thereof. Other therapeutic agents include squalamine, 15 carbonic anhydrase inhibitors, alpha agonists, prostamides, prostaglandins, antiparasitics, antifungals, and derivatives thereof. In a preferred embodiment of the invention, the therapeutically active agent or therapeutic agent 20 comprises a retinoid, a prostaglandin, a tyrosine kinase inhibitor, a glucocorticoid, an androgenic steroid, an estrogenic steroid, or a non-estrogenic steroid, an intracellular adhesion molecule inhibitor, or an alpha 2-adrenergic receptor agonist. In one specific 25 embodiment, the therapeutic agent is triamcinolone acetonide. The therapeutic agent of the present compositions may include any or all salts and prodrugs or precursors of the therapeutic agents, including those specifically 30 identified herein.

WO 2005/072701 PCT/US2005/001371 is In certain embodiments, the therapeutic component of the composition may comprise particles including more than one therapeutic agent. In other words, the therapeutic component of the composition may include a 5 first therapeutic agent, and a second therapeutic agent, or a combination of therapeutic agents. Examples of therapeutic agents include those identified above in any combination. One or more of the therapeutic agents in such compositions may be formed as or present in 10 particles, as disclosed herein. The compositions disclosed herein may include a therapeutic component that comprises, consists essentially of, or consists of, a population of particles including a therapeutic agent. Each of the 15 particles have a size. When the particles are grouped to define a population of particles, the population may have an effective average particle size that corresponds to the average size of the particles of that population. The size of the particles may be uniformly distributed 20 in any given population. For example, the size of particles in a population may be symmetrically distributed about the mean size of the particles. Or, the size of the particles may be distributed asymmetrically. For example, a population of particles 25 may have an effective average particle size that is skewed away from the median particle size for a population of particles. In certain embodiments, the compositions comprise a population of particles including a first therapeutic 30 agent and a population of particles including a second WO 2005/072701 PCT/US2005/001371 16 therapeutic agent. Thus, in at least one embodiment, a composition comprises a population of particles having an effective average particle size that is effective to form concentrated regions of the therapeutic agent. In 5 certain embodiments, a population of particles has an average size effective to promote phagocytosis of the particles by RPE cells. In other embodiments, a population of particles has an average size effective to promote pinocytosis by RPE cells. The compositions 10 disclosed herein may thus have a population of a predetermined number of particles with a desired or predetermined size. This may provide enhanced therapeutic effects relative to existing compositions that do not have populations of a predetermined number 15 of particles of a specific size. For example, some compositions may include "fines" of therapeutic agent particles. Fines, as used herein, may be understood to be particles that are randomly formed during the manufacture of the particles. Fines may be relatively 20 small, but because they occur randomly, they do not provide a desired therapeutic effect. In certain embodiments, such as embodiments in which the particles promote phagocytosis, the particles may have an average size of about 3000 nanometers. 25 Usually, the particles will have an effective average size less than about 3000 nanometers. In more specific embodiments, the particles may have an effective average particle size about an order of magnitude smaller than 3000 nanometers. For example, the particles may have an 30 effective average particle size of less than about 500 WO 2005/072701 PCT/US2005/001371 17 nanometers. In further embodiments, the particles may have an effective average particle size of less than about 400 nanometers, and in still further embodiments, a size less than about 200 nanometers. Reducing the 5 size of the particles may be effective to cause the particles to form concentrated regions by pinocytosis mechanisms as compared to phagocytosis mechanisms. In addition, a composition may include a therapeutic component with more than one population of 10 particles, each population having a different effective average particle size. In one specific embodiment, the therapeutic component may comprise a first population of particles including a therapeutic agent having an effective average particle size of less than about 200 15 nanometers, a second population of particles having an effective average particle size in a range of about 200 nanometers to about 400 nanometers, and a third population of particles having an effective average particle size in a range of about 400 nanometers to 20 about 3000 nanometers. In at least one embodiment, the particles of the composition may comprise, consist essentially of, or consist of, a therapeutic agent and a polymer suitable for administration to the posterior segment of an eye. 25 The polymer in combination with the therapeutic agent may be understood to be a polymeric component. In some embodiments, the particles comprise materials other than D,L-polylactide (PLA) or latex (carboxylate modified polystyrene beads) . In certain embodiments, the polymer 30 component may comprise a polysaccharide. For example, WO 2005/072701 PCT/US2005/001371 18 the polymer component may comprise a mucopolysaccharide. In at least one specific embodiment, the polymer component is hyaluronic acid. However, in additional embodiments, the polymeric 5 component may comprise any polymeric material useful in a body of a mammal, whether derived f rom a natural source or synthetic. Some additional examples of useful polymeric materials for the purposes of this invention include carbohydrate based polymers such as 10 methylcellulose, carboxymethylcellulose, hydroxymethylcellulose hydroxypropylcellulose, hydroxyethylcellulose, ethyl cellulose, dextrin, cyclodextrins, alginate, hyaluronic acid and chitosan, protein based polymers such as gelatin, collagen and 15 glycolproteins, hydroxy acid polyesters such as polylactide-coglycolide (PLGA) , polylactic acid (PLA) , polyglycolide, polyhydroxybutyric acid, polycaprolactone, polyvalerolactone, polyphosphazene, and polyorthoesters. Polymers can also be crosslinked, 20 blended or used as copolymers in the invention. Other polymer carriers include albumin, polyanhydrides, polyethylene glycols, polyvinyl polyhydroxyalkyl methacrylates, pyrrolidone and polyvinyl alcohol. Some examples of non-erodible polymers include 25 silicone, polycarbonates, polyvinyl chlorides, polyamides, polysulfones, polyvinyl acetates, polyurethane, ethylvinyl acetate derivatives, acrylic resins, crosslinked polyvinyl alcohol and crosslinked polyvinylpyrrolidone, polystyrene and cellulose acetate 30 derivatives.

WO 2005/072701 PCT/US2005/001371 19 These additional polymeric materials may be useful with any of the therapeutic agents. For example, particles. of PLA or PLGA may be coupled to triamcinolone acetonide, in one embodiment. 5 The particles of the therapeutic agent or agents may also be combined with a pharmaceutically acceptable vehicle component in the manufacture of a composition. In other words, a composition, as disclosed herein, may comprise a therapeutic component, as discussed above, 10 and an effective amount of a pharmaceutically acceptable vehicle component. In at least one embodiment, the vehicle component is aqueous-based. For example, the composition may comprise water. In certain embodiments, the vehicle component may 15 also include an effective amount of at least one of a viscosity inducing component, a resuspension component, a preservative component, a tonicity component and a buffer component. In some embodiments, the compositions disclosed herein include. no added preservative 20 component. In other embodiments, a composition may include an added preservative component. In addition, the composition may be included with no resuspension component. The aqueous vehicle component is advantageously 25 ophthalmically acceptable and may also include one or more conventional excipients useful in ophthalmic compositions. The present compositions preferably include a major amount of liquid water. The present compositions may 30 be, and are preferably, sterile, for example, prior to WO 2005/072701 PCT/US2005/001371 20 being used in the eye. The present compositions preferably include at least one buffer component in an amount effective to control the pH of the composition and/or at least one 5 tonicity component in an amount effective to control the tonicity or osmolality of the compositions. More preferably, the present compositions include both a buffer component and a tonicity component. The buffer component and tonicity component may be 10 chosen from those which are conventional and well known in the ophthalmic art. Examples of such buffer components include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers,. borate buffers and the like and 15 mixtures thereof. Phosphate buffers are particularly useful. Useful tonicity components include, but are not limited to, salts, particularly sodium chloride, potassium chloride, any other suitable ophthalmically acceptably tonicity component and mixtures thereof. 20 The amount of buffer component employed preferably is sufficient to maintain the pH of the composition in a range of about 6 to about 8, more preferably about 7 to about 7.5. The amount of tonicity component employed preferably is sufficient to provide an osmolality to the 25 present compositions in a range of about 200 to about 400, more preferably about 250 to about 350, mOsmol/kg respectively. Advantageously, the present compositions are substantially isotonic. The present compositions may include one or more 30 other components in amounts effective to provide one or WO 2005/072701 PCT/US2005/001371 21 more useful properties and/or benefits to the present compositions. For example, although the present compositions may be substantially free of added preservative components, in other embodiments, the 5 present compositions include effective amounts of preservative components, preferably such components which are more compatible with or friendly to the tissue in the posterior segment of the eye into which the composition is placed than benzyl alcohol. Examples of 10 such preservative components include, without limitation, benzalkonium, chloride, methyl and ethyl parabens, hexetidine, chlorite components, such as stabilized chlorine dioxide, metal chlorites and the like, other ophthalmically acceptable preservatives and 15 the like and mixtures thereof. The concentration of the preservative component, if any, in the present compositions is a concentration effective to preserve the composition, and is often in a range of about 0.00001% to about 0.05% or about 0.1% (w/v) of the 20 composition. In addition, the present composition may include an effective amount of resuspension component effective to facilitate the suspension or resuspension of the therapeutic component particles in the present 25 compositions. As noted above, in certain embodiments, the present compositions are free of added resuspension components. In other embodiments of the present compositions effective amounts of resuspension components are employed, for example, to provide an 30 added degree of insurance that the therapeutic component WO 2005/072701 PCT/US2005/001371 22 particles remain in suspension, as desired and/or can be relatively easily resuspended in the present compositions, such resuspension be desired. Advantageously, the resuspension component employed in 5 accordance with the present invention, if any, is chosen to be more compatible with or friendly to the tissue in the posterior segment of the eye into which the composition is placed then polysorbate 80. Any suitable resuspension component may be employed 10 in accordance with the present invention. Examples of such resuspension components include, - without limitation, surfactants such as poloxanes, for example, sold under the trademark Pluronic*; tyloxapol; sarcosinates; polyethoxylated castor oils, other 15. surfactants and the like and mixtures thereof. One very useful class of resuspension components are those selected from vitamin derivatives. Although such materials have been previously suggested for use as surfactants in ophthalmic compositions, they have been 20 found to be effective in the present compositions as resuspension components. Examples of useful vitamin derivatives include, without limitation, Vitamin E tocopheryl polyethylene glycol succinates, such as Vitamin E tocopheryl polyethylene glycol 1000 succinate 25. (Vitamin E TPGS). Other useful vitamin derivatives include, again without limitation, Vitamin E tocopheryl polyethylene glycol succinamides, such as Vitamin E tocopheryl polyethylene glycol 1000 succinamide (Vitamin E TPGSA) wherein the ester bond between polyethylene 30 glycol and succinic acid is replaced by an amide group.

WO 2005/072701 PCT/US2005/001371 23 The presently useful resuspension components are present, if at all, in the compositions in accordance with the present invention in an amount effective to facilitate suspending the particles in the present 5 compositions, for example, during manufacture of the compositions or thereafter. The specific amount of resuspension component employed may vary over a wide range depending, for example, . on the specific resuspension component being employed, the specific 10 composition in which the resuspension component is being employed and the like factors. Suitable concentrations o-f the resuspension component, if any, in the present compositions are often in a range of about 0.01% to about 5%, for example, about 0.02% or about 0.05% to 15 about 1.0% (w/v) of the composition. The compositions disclosed herein may include' a viscosity inducing component in an amount effective in providing an increased viscosity to the composition relative to an identical composition without the 20 viscosity inducing component. The viscosity inducing component may comprise at least one viscoelastic agent. Any suitable viscosity inducing component, for example, ophthalmically acceptable viscosity inducing component, may be employed in accordance with the 25 present invention. Many such viscosity inducing components have been proposed and/or used in ophthalmic compositions used on or in the eye. The viscosity inducing component is present in an amount effective in providing the desired viscosity to the composition. 30 Advantageously, the viscosity inducing component is WO 2005/072701 PCT/US2005/001371 24 present in an amount in a range of about 0.5% or about 1.G% to. about 5% or about 10% or about 20% (w/v) of the composition. The specific amount of the viscosity inducing component employed depends upon a number of 5 factors including, for example and without limitation, the specific viscosity inducing component being employed, the molecular weight of the viscosity inducing component being employed, the viscosity desired for the present composition being produced and/or used and the 10 like factors. The viscosity inducing component is chosen to provide at least one advantage, and preferably multiple advantages, to the present compositions, for example, in terms of each of injectability into the posterior segment of the eye, viscosity, sustainability 15 of the corticosteroid component particles in suspension, for example, in substantially uniform suspension, for a prolonged period of time without resuspension processing, compatibility with the tissues in the posterior segment of the eye into which the composition 20 is to be placed and the like- advantages. More preferably, the selected viscosity inducing component is effective to provide two or more of the above-noted benefits, and still more preferably to provide all of the above-noted benefits. 25 The viscosity inducing component preferably comprises a polymeric component and/or at least one viscoelastic agent, such as those materials which are useful in ophthalmic surgical procedures. Examples of useful viscosity inducing components 30 include, but are not limited to, hyaluronic acid, WO 2005/072701 PCT/US2005/001371 25 carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, derivatives thereof and mixtures 5 thereof. The molecular weight of the presently useful viscosity inducing components may be in a range of about 10,000- Daltons or less to about 2 million Daltons or more. In one particularly useful embodiment, the 10 molecular weight of the viscosity inducing component is in a range of about 100,000 Daltons or about 200,000 Daltons to about 1 million Daltons or about 1.5 million Daltons. Again, the molecular weight of the viscosity inducing component useful in accordance with the present 15 invention, may vary over a substantial range based on the type of viscosity inducing component employed, and the desired final viscosity of the present composition in question, as well as, possibly one or more other factors. 20 In one very useful embodiment, a viscosity inducing component is a hyaluronate component, for example, a metal hyaluronate component, preferably selected from alkali metal hyaluronates, alkaline earth metal hyaluronates and mixtures thereof, and still more 25 preferably selected from sodium hyaluronates, and mixtures thereof. The molecular weight of such hyaluronate component preferably is in a range of about 50,000 Daltons or about 100,000 Daltons to about 1.3 million Daltons or about 2 million Daltons. In one 30 embodiment, the present compositions include a WO 2005/072701 PCT/US2005/001371 26 hyaluronate component in an amount in a range about 0.05% to about 0.5% (w/v). In a further useful embodiment, the hyaluronate component is present in an amount in a range of about 1% to about 4% (w/v) of the S composition. In this latter case, the very high polymer viscosity forms a gel that slows particle sedimentation rate to the extent that often no resuspension processing is necessary over the estimated shelf life, for example, at least about 2 years, of the composition. Such a 10 composition may be marketed in pre-filled syringes since the gel cannot be easily removed by a needle and syringe from a bulk container. In at least one embodiment, the viscosity inducing component is selected from the group consisting of 15 hyaluronic acid, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, derivatives thereof and mixtures thereof. In certain embodiments, 20 the viscosity inducing component comprises a hyaluronate component, such as a sodium hyaluronate. Advantageously, it has been discovered that compositions which include a therapeutic component comprising a therapeutic agent in the form of particles fabricated 25 from a hyaluronic acid component provide an effective viscosity to the composition as well as the desired formation of concentrated regions of the therapeutic agent In at least one embodiment, an ophthalmically 30 acceptable composition comprises a population of WO 2005/072701 PCT/US2005/001371 27 particles of triamcinolone acetonide having an effective average particle size less than about 3000 nanometers. As discussed herein, when a pinocytotic mechanism is desired for the formation of concentrated regions of the 5 therapeutic agent, the composition may have at least a major portion of the population of particles with a size less than about 500 nanometers. In at least one other embodiment of the invention, a population of particles of triamcinolone acetonide has 10 an effective average particle size less than about 3000 nanometers. For example, the population of particles may have an effective average particle size less than about 500 nanometers. In at least one embodiment, the population of particles has an effective average 15 particle size of between about 200 and about 400 nanometers. The population of particles of triamcinolone acetonide may be provided in a liquid carrier component, and preferably, an ophthalmically acceptable liquid 20 carrier component. One example of a liquid carrier component may include hyaluronic acid. The combination of the particles and the liquid carrier component may be provided in a container, such as a vial and/or a dispensing apparatus. For example, when the population 25 of particles is administered to a posterior segment of an eye of a patient, the population may be provided in a syringe that is configured to administer the particles to an eye, and preferably, to a posterior segment of an eye, as discussed herein. 30 In at least one embodiment, the particles comprise WO 2005/072701 PCT/US2005/001371 28 a combination of triamcinolone acetonide and hyaluronic acid. The hyaluronic acid is believed to stabilize the particles of triamcinolone acetonide. The particles have a size, such as a width, a length, a diameter, an 5 area, or a volume, effective to facilitate transfer of the particles into the RPE when the particles are administered to an eye. In at least one other embodiment of the invention, a poorly soluble steroid, such as a corticosteroid, is 10 provided as small particles. The particles 'preferably have an effective average particle size less than about 3000 nanometers, preferably less than about 400 nanometers, and more preferably, less than about 200 nanometers. The steroid preferably has a solubility of 15 less than about 10 mg/mL. In at least one embodiment, the poorly soluble steroid is triamcinolone acetonide. The particles may be formed by mixing the poorly soluble steroid with a hyaluronate component. Stabilization of the particles may be obtained by one or more surface 20 modifications of the steroid with hyaluronic acid or sodium hyaluronate. The particles may be provided in a pharmaceutical composition, such as compositions disclosed herein. In at least one embodiment, a composition comprises a first 25 population of particles having a size less than 200 nanometers, a second population of particles having an effective average particle size between about 200 nanometers and about 400 nanometers, and a third population of particles having an effective average 30 particle size between about 400 nanometers and about WO 2005/072701 PCT/US2005/001371 29 30-00 nanometers. In additional embodiments, a composition may have only two populations of particles with different effective average particle sizes. Such compositions are substantially free, and preferably are 5 entirely free, of fines of the therapeutic agent, as discussed herein. The particles of the therapeutic agent disclosed herein,. including triamcinolone acetonide, may be manufactured by subjecting a composition, which may not 10 necessarily be an ophthalmic composition, of relatively large particles of the therapeutic agent and a polymeric component acceptable for administration into a posterior segment of an eye of a patient to conditions that are effective to reduce the relatively large particles to 15. smaller particles having an effective average particle size that is effective to form concentrated regions of the therapeutic agent when placed in an eye. For example, the particles may be reduced to about 3000 nanometers or less in size. The polymeric component may 20 be present in an amount effective in stabilizing the smaller particles in the product composition. In at least one embodiment, the product composition is subjected to a milling step. For example, the particles may be exposed to a ball mill. As one 25 example, hyaluronic acid can be added to particles of the therapeutic agent in an amount from about 10% to about 200% of the active therapeutic agent on a weight basis. Hyaluronic acid may be added in the form of an aqueous solution. The therapeutic agent may then be 30 milled in the hyaluronic acid solution until the mean WO 2005/072701 PCT/US2005/001371 30 average particle size equals the desired range. The particles may be sorted into different populations according to size differences. For example, the particles may be sorted by passing the particles 5 through a series of filters having a series of openings of different sizes allowing progressively larger particles to be separated from smaller particles. In certain embodiments, the particles may be prepared using methods such as those disclosed in U.S. 10 Patent Nos. 6,387,409; 5 ,5 6 5

,

1 8 8 ; and/or 5,552,160, the contents of all of which are hereby incorporated by reference. Compositions can be prepared using suitable blending/processing techniques or techniques, for 15 example, one or more conventional blending techniques. The preparation processing should be chosen to provide the present compositions in forms which are useful for placement or injection into the posterior segments of eyes of humans or animals. In one. embodiment a 20 concentrated therapeutic component dispersion is made by combining therapeutic agent in the form of particles, as discussed herein, with water and the excipients to be included in the final ophthalmic composition. The ingredients may be mixed to disperse the therapeutic 25 component and then may be autoclaved. A composition including particles, such as the particles described above, may be administered to a patient to provide a treatment to a patient. For example, the composition may be administered to a human 30 or animal patient to treat an ocular condition or WO 2005/072701 PCT/US2005/001371 3,1 disease. Among the diseases/conditions which can be treated or addressed in accordance with the present invention include, without limitation, the following: S MACULOPATHIES/RETINAL DEGENERATION: Non-Exudative Age Related Macular Degeneration (ARMD), Exudative Age Related Macular Degeneration (ARMD), Choroidal Neovascularization, Diabetic Retinopathy, Acute Macular Neuroretinopathy, Central Serous Chorioretinopathy, 10 Cysto-id Macular Edema, Diabetic Macular Edema. UVEITIS/RETINITIS/CHOROIDITIS: Acute Multifocal Placoid Pigment Epitheliopathy, Behcet's Disease, Birdshot Retinochoroidopathy, Infectious (Syphilis, Lyme, Tuberculosis, Toxoplasmosis) , Intermediate Uveitis 15 (Pars Planitis), Multifocal Choroiditis, Multiple Evanescent White Dot Syndrome (MEWDS), Ocular Sarcoidosis, Posterior Scleritis, Serpignous Choroiditis, Subretinal Fibrosis and Uveitis Syndrome, Vogt-Koyanagi-Harada Syndrome. 20 VASCULAR DISEASES/EXUDATIVE DISEASES: Retinal Arterial Occlusive Disease, Central Retinal Vein Occlusion, Disseminated Intravascular Coagulopathy, Branch Retinal Vein Occlusion, Hypertensive Fundus Changes, Ocular Ischemic Syndrome, Retinal Arterial 25 Microaneurysms, Coat's Disease, Parafoveal Telangiectasis, Hemi-Retinal Vein Occlusion, Papillophlebitis, Central Retinal Artery Occlusion, Branch Retinal Artery Occlusion, Carotid Artery Disease (CAD) , Frosted Branch Angitis, Sickle Cell Retinopathy 30 and other Hemoglobinopathies, Angioid Streaks, Familial WO 2005/072701 PCT/US2005/001371 32 Exudative Vitreoretinopathy, Eales Disease. TRAUMATIC/SURGICAL: Sympathetic Ophthalmia, Uveitic Retinal Disease, Retinal Detachment, Trauma, Laser, PDT, Photocoagulation, Hypoperfusion During Surgery, 5 Radiation Retinopathy, Bone Marrow Transplant Retinopathy. PROLIFERATIVE DISORDERS: Proliferative Vitreal Retinopathy and Epiretinal Membranes, Proliferative Diabetic Retinopathy. 10 INFECTIOUS DISORDERS: Ocular Histoplasmosis, Ocular Toxocariasis, Presumed Ocular Histoplasmosis- Syndrome (POHS), Endophthalmitis, Toxoplasmosis, Retinal Diseases Associated with HIV Infection, Choroidal Disease Associated with HIV Infection, Uveitic Disease 15 Associated with HIV Infection, Viral Retinitis, Acute Retinal Necrosis, Progressive Outer Retinal Necrosis, Fungal Retinal Diseases, Ocular Syphilis, Ocular Tuberculosis, Diffuse Unilateral Subacute Neuroretinitis, Myiasis. 20 GENETIC DISORDERS: Retinitis Pigmentosa, Systemic Disorders with Accosiated Retinal Dystrophies, Congenital Stationary Night Blindness, Cone Dystrophies, Stargardt's Disease and Fundus Flavimaculatus, Best's Disease, Pattern Dystrophy of the Retinal Pigmented 25 Epithelium, X-Linked Retinoschisis, Sorsby's Fundus Dystrophy, Benign Concentric Maculopathy, Bietti's Crystalline Dystrophy, pseudoxanthoma elasticum. RETINAL TEARS/HOLES: Retinal Detachment, Macular Hole, Giant Retinal Tear. 30 TUMORS: Retinal Disease Associated with Tumors, WO 2005/072701 PCT/US2005/001371 33 Congenital Hypertrophy of the RPE, Posterior Uveal Melanoma, Choroidal Hemangioma, Choroidal Osteoma, Choroidal Metastasis, Combined Hamartoma of the Retina and Retinal Pigmented Epithelium, Retinoblastoma, 5 Vasoproliferative Tumors of the Ocular Fundus, Retinal Astrocytoma, Intraocular Lymphoid Tumors. MISCELLANEOUS: Punctate Inner Choroidopathy, Acute Posterior Multifocal Placoid Pigment Epitheliopathy, Myopic Retinal Degeneration, Acute Retinal Pigment 10 Epithelitis and the like. In one embodiment, a composition, such as the compositions disclosed herein, is administered to a posterior segment of an eye of a human or animal patient, and preferably, a living human or animal. In 15 at least one embodiment, a composition is administered without accessing the subretinal space of the eye. For example, a method of treating a patient may include injecting the composition directly into the posterior chamber of the eye. In other embodiments, a method of 20 treating a patient may comprise administering a composition to the patient by at least one of intravitreal injection, subconjuctival injection, sub tenon injections, retrobulbar injection, and suprachoroidal injection. 25 In at least one embodiment, a method of treating a posterior segment ocular disease comprises administering a population of particles, or a composition containing such particles, as disclosed herein to a patient by at least one of intravitreal injection, subconjuctival 30 injection, sub-tenon injection, retrobulbar injection, H:\mdt\nterwoven\NRPortbl\DCC\MDT\6428241_ 1.doc-17/06/ 2014 34 and suprachoroidal injection. A syringe apparatus including, an appropriately sized needle, for example, a 27 gauge needle or a 30 gauge needle, can be effectively used to inject the composition with the posterior segment of an eye of a human or . animal . The 5 present methods may comprise a single injection into the posterior segment of an eye or may involve repeated injections, for example over periods of time ranging from about one week or about 1 month or about 3 months to about 6 months or about 1 year or longer. In another aspect of the present invention, the particles 10 and/or compositions disclosed herein are used in the manufacture of a medicament that is effective to treat one or more ocular conditions, such as an ocular condition affecting the posterior segment of an eye of a patient, and including the conditions identified herein. 15 While this invention has been described . with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced within the scope of the following claims. 20 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or 25 step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission 30 or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims (20)

1. A pharmaceutical composition for placement in a posterior segment of an eye of a human or animal, the composition 5 comprising: a therapeutic component comprising particles of a poorly soluble therapeutic agent and hyaluronic acid or a salt thereof, the particles having a size effective to form concentrated regions of the therapeutic agent in the retinal pigmented epithelium (RPE) 10 of an eye of a human or animal when administered to a posterior segment of the eye of the human or animal, wherein the therapeutic agent is not triamcinolone.

2. The composition of claim 1, wherein the particles have 15 a size effective to form concentrated regions having a concentration of the therapeutic agent that is greater relative to the concentration of the therapeutic agent in the composition when administered to the eye. 20

3. The composition of claim 1 or claim 2, wherein the particles are sized to be distributed in the eye to reduce toxicity associated with the therapeutic agent in an anterior tissue of the eye. 25

4. The composition of any one of claims 1 to 3, wherein the particles have an average size effective to promote phagocytosis of the particles by the RPE.

5. The composition of any one of claims 1 to 4, wherein 30 the particles have an average size effective to promote pinocytosis by the RPE.

6. The composition of any one of claims 1 to 5, wherein the therapeutic agent is formed as particles having an effective 35 average particle size of less than about 3000 nanometers, an H:\mdt\Interwoven\NRPortbl\DCC\MDT\6428241_1.doc-17/06/2014 36 effective average particle size of less than about 500 nanometers, an effective average particle size of less than about 400 nanometers or an effective average particle size of less than about 200 nanometers. 5

7. The composition of any one of claims 1 to 5, wherein the therapeutic component comprises a first population of particles having an effective average particle size of less than about 200 nanometers, a second population of particles having an effective 10 average particle size in a range of about 200 nanometers to less than 400 nanometers, and a third population of particles having an effective average particle size in a range of about 400 nanometers to less than about 3000 nanometers. 15

8. The composition of any one of claims 1 to 7, wherein the therapeutic agent has a solubility in water at 25 0 C of less than about 10 mg/ml.

9. The composition of any one of claims 1 to 8, wherein 20 the therapeutic agent comprises a corticosteroid.

10. The composition of any one of claims 1 to 92, further comprising an effective amount of a pharmaceutically acceptable vehicle component. 25

11. The composition of claim 10, wherein the vehicle component is aqueous-based.

12. The composition of claim 10 or claim 11, wherein the 30 therapeutic agent is present in an amount of up to about 25% (w/v) of the composition.

13. A method of treatment comprising administering the composition of any one of claims 1 to 12 to a posterior segment of 35 an eye of a human or animal, thereby obtaining a desired H:\mdt\Interwoven\NRPortbl\DCC\MDT\6428241_1.doc- 17/06/2014 37 therapeutic effect.

14. The method of claim 13, wherein the administering step comprises intravitreal injecting, subconjunctival injecting, sub 5 tenon injecting, retrobulbar injecting and/or suprachoroidal injecting.

15. A pharmaceutical composition for placement in a posterior segment of an eye of a human or animal, the composition 10 comprising: a therapeutic component comprising particles of a poorly soluble steroid and hyaluronic acid or a salt thereof, wherein the particles are sized and distributed in the composition to form concentrated regions of the steroid in the retinal pigmented 15 epithelium (RPE) of the human or animal when administered to a posterior segment of the eye of the human or animal, wherein the poorly soluble steroid is not triamcinolone.

16. The composition of claim 15, wherein the therapeutic 20 component comprises a corticosteroid.

17. The composition of claim 15, wherein the therapeutic component comprises a first population of particles containing a poorly soluble steroid, and a second population of particles 25 containing the poorly soluble steroid, the second population having an effective average particle size that is different than the first population.

18. The composition of any one of claims 15 to 17, wherein 30 the particles have a size from about 200 nanometers to about 3000 nanometers.

19. The composition of any one of claims 15 to 18, further comprising an ophthalmically acceptable vehicle component. 35 H:\mdt\Interwoven\NRPortbl\DCC\M DT\6428241_1.doc-17/06/2014 38

20. Use of a composition of any one of claims 1 to 12 or a pharmaceutical composition of any one of claims 15 to 29 in the manufacture of a medicament for treating an ocular condition.